Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 160

Results For "IDA"

1800 News Found

Private equity firm Carlyle partners with Viyash Life Sciences for pharma platform
News | November 17, 2021

Private equity firm Carlyle partners with Viyash Life Sciences for pharma platform

Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players


Pfizer seeks EUA from U.S. FDA for Covid-19 drug
Biotech | November 17, 2021

Pfizer seeks EUA from U.S. FDA for Covid-19 drug

If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2


Vicco Labs moves to sustainable Platina tube packaging
Packaging | November 16, 2021

Vicco Labs moves to sustainable Platina tube packaging

Platina 250, 300 & 350 Lamitubes have been recognized by the Association of Plastic Recyclers (APR), USA as meeting or exceeding the strict APR HDPE critical guidance criteria on recyclability


Pre-diabetes is a much more serious issue in India: Fitterfly
News | November 16, 2021

Pre-diabetes is a much more serious issue in India: Fitterfly

Two out of three people under the age of 40 are at risk of prediabetes


NAL drone delivers Covid-19 vaccine at a remote location
Public Health | November 15, 2021

NAL drone delivers Covid-19 vaccine at a remote location

The octocopter has successfully delivered 50 vials of Covid-19 vaccines along with syringes in a special container from Chandapura PHC to Haragadde PHC


Natco Pharma PAT at Rs 65.1 cr. in Q2FY22
News | November 12, 2021

Natco Pharma PAT at Rs 65.1 cr. in Q2FY22

Natco Pharma has reported consolidated financial results for the period ended September 30, 2021


Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
News | November 12, 2021

Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.


Jubilant Biosys expands Chemistry Innovation Research Centre
Supply Chain | November 12, 2021

Jubilant Biosys expands Chemistry Innovation Research Centre

The centre has an initial capacity of 500 FTEs


Covaxin well tolerated with no safety concerns: Lancet
News | November 12, 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%


Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22
News | November 11, 2021

Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22

The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.